Examples: breast cancer, NCT03147287, pd-l1

Top 100 results for: "brain cancer"

Not Enrolling

A pilot surgical trial to evaluate early immunologic pharmacodynamic parameters for the PD-1 checkpoint inhibitor, pembrolizumab (MK-3475), in patients with surgically accessible recurrent/progressive glioblastoma

Trial Description: This research study is studying an immunotherapy as a possible treatment for Glioblastoma

  • Conditions: brain cancer
  • Phase: I
  • Trial ID: NCT02852655
  • Protocol ID: 16-225

Enrolling

Phase 0/I study of AMG 232 concentrations in brain tissue in patients with recurrent glioblastoma and of AMG 232 in combination with radiation in patients with newly diagnosed glioblastoma and unmethylated MGMT promoters

Trial Description: This phase I trial studies the side effects and best dose of MDM2 inhibitor KRT-232 in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent). MDM2 inhibitor KRT-232 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

  • Conditions: glioblastoma, gliosarcoma, mgmt-unmethylated glioblastoma, recurrent glioblastoma
  • Phase: I
  • Trial ID: NCT03107780
  • Protocol ID: 17-453

Enrolling

A Phase I Study of the Treatment of Recurrent Malignant Glioma with rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and immunomodulation with Cyclophosphamide (Dana Farber Cancer Institute/ Brigham and Women’s Hospital)

Trial Description: This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.

  • Conditions: anaplastic oligodendroglioma of brain (diagnosis), astrocytoma, brain cancer, brain tumor, ependymoma, ganglioglioma, glioblastoma, glioblastoma multiforme, glioma, malignant astrocytoma, malignant glioma of brain, mixed oligo-astrocytoma, oligodendroglioma, pylocytic/pylomyxoid astrocytoma
  • Phase: I
  • Trial ID: NCT03152318
  • Protocol ID: 16-557

Enrolling

A double-blind, phase II randomized study of brain-directed stereotactic radiation with or without AGuIX gadolinium-based nanoparticles in the management of brain metastases at higher risk of local recurrence with radiation alone

Trial Description: The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.

  • Conditions: aguix, brain cancer, brain metastases, brain tumor, breast cancer, colorectal cancer, cystic, gastrointestinal cancer, her2-positive breast cancer, lung cancer, melanoma, nanoparticle, srs, srt, stereotactic radiation, whole brain radiation
  • Phase: II
  • Trial ID: NCT04899908
  • Protocol ID: 20-240

Enrolling

Screening MRI of the brain in patients with metastatic breast cancer managed with first/second line chemotherapy or inflammatory breast cancer managed with definitive intent: A prospective study

Trial Description: This research study is studying the usefulness of magnetic resonance imaging (MRI) to screen for brain metastases (spread of the breast cancer to the brain).

  • Conditions: breast cancer, her2-positive breast cancer, hormone receptor positive malignant neoplasm of breast, inflammatory breast cancer, metastatic breast cancer, triple negative breast cancer
  • Phase: II
  • Trial ID: NCT04030507
  • Protocol ID: 19-066

Enrolling

Phase II Trial of GDC-0084 in combination with Trastuzumab for Patients with HER2-Positive Breast Cancer Brain Metastases

Trial Description: This research study is studying a drug called GDC-0084 as a possible treatment for HER2-Positive Breast Cancer. The drugs involved in this study are: - GDC-0084 - Trastuzumab (Herceptin®)

  • Conditions: breast cancer
  • Phase: II
  • Trial ID: NCT03765983
  • Protocol ID: 18-516

Not Enrolling

A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis

Trial Description: This research study is studying the combination of a drug called atezolizumab and a radiation procedure called stereotactic radiosurgery (SRS) as a possible treatment for triple-negative breast cancer that has spread to the brain. The interventions involved in this study are: - Atezolizumab - Stereotactic radiosurgery (SRS)

  • Conditions: breast cancer
  • Phase: II
  • Trial ID: NCT03483012
  • Protocol ID: 17-519

Enrolling

Whole brain radiation versus stereotactic radiation in patients with 5-20 brain metastases: A phase III, randomized clinical trial

Trial Description: This research study is studying two different types of radiation as treatment for brain metastases (tumors in the brain that spread from a cancer that originated elsewhere in the body)

  • Conditions: brain metastases
  • Phase: III
  • Trial ID: NCT03075072
  • Protocol ID: 16-305

Enrolling

Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy

Trial Description: This research study is examining a preventive skin care regimen for children diagnosed with a brain tumor and receiving anti-cancer therapy with a MEK, Pan-RAF, or BRAF inhibitor.

  • Conditions: cns tumor childhood, pediatric cancer, skin inflammation
  • Phase: II
  • Trial ID: NCT04479514
  • Protocol ID: 19-579

Not Enrolling

FEASIBILITY OF THE LUM IMAGING SYSTEM FOR IN VIVO AND EX VIVO DETECTION OF CANCER IN SUBJECTS WITH LOW GRADE GLIOMAS, GLIOBLASTOMAS AND CANCER METASTASES TO THE BRAIN

Trial Description: The overall objective of this study is to assess the safety and efficacy of the LUM Imaging System in imaging primary and metastatic cancer in the brain. This includes selecting a dose to determine the initial efficacy of LUM015 for the molecular imaging of low-grade gliomas, glioblastomas and cancer masses that have metastasized to the brain.

  • Conditions: glioblastoma, low grade glioma of brain, metastasis to brain
  • Phase: Feasibility / Pilot
  • Trial ID: NCT03717142
  • Protocol ID: 18-463

Enrolling

Stereotactic radiation in patients with small cell lung cancer and 1-6 brain metastases: A single arm, phase II trial

Trial Description: This research study is studying stereotactic radiation (focused/pinpoint radiation that targets each individual tumor but not the surrounding brain) instead of whole-brain radiation (radiation targeting the entire brain) as a possible treatment for patients with small cell lung cancer and 1-10 brain metastases. The intervention involved in this study is: -Stereotactic (focused, pinpoint) radiation

  • Conditions: brain metastases, small cell lung cancer
  • Phase: II
  • Trial ID: NCT03391362
  • Protocol ID: 17-550

Enrolling

A Phase II Trial of HKI-272 (Neratinib), Neratinib) and Capecitabine, and Neratinib and Ado-Trastuzumab Emtansine (T-DM1) for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases

Trial Description: The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). In this research study, the investigators are looking to see how well neratinib works to decrease the size of or stabilize breast cancer that has spread to the brain. The investigators are also looking at how previous treatments have affected your thinking (or cognition) and how much neratinib reaches the central nervous system.

  • Conditions: breast cancer
  • Phase: II
  • Trial ID: NCT01494662
  • Protocol ID: 11-344

Not Enrolling

A PHASE 3 OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY OF NKTR-102 VERSUS TREATMENT OF PHYSICIAN’S CHOICE (TPC) IN PATIENTS WITH METASTATIC BREAST CANCER WHO HAVE STABLE BRAIN METASTASES AND HAVE BEEN PREVIOUSLY TREATED WITH AN ANTHRACYCLINE, A TAXANE, AND CAPECITABINE

Trial Description: This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).

  • Conditions: breast cancer, metastasis
  • Phase: III
  • Trial ID: NCT02915744
  • Protocol ID: 16-553

Enrolling

S1827: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Trial Description: This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.

  • Conditions: extensive stage lung small cell carcinoma, limited stage lung small cell carcinoma, lung small cell carcinoma
  • Phase: III
  • Trial ID: NCT04155034
  • Protocol ID: 20-484

Enrolling

An open label phase Ib dose finding study of BI 836880 in combination with BI 754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors

Trial Description: This study has 2 parts. The first part was open to adults with advanced non-small cell lung cancer. The second part was open also to adults with other types of advanced cancer of the lung, brain, skin, and liver. After early encouraging results, more people with liver cancer can now take part in the study. The participants get a combination of two medicines called BI 836880 and ezabenlimab. BI 836880 is a type of an antibody that blocks new blood vessel formation. New blood vessels are needed by the tumour to continue growing. Ezabenlimab is an antibody that may help

  • Conditions: neoplasms, non-squamous non-small-cell lung cancer
  • Phase: I
  • Trial ID: NCT03468426
  • Protocol ID: 19-823

Enrolling

A Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Trial Description: NUV-422-02 is a first-in-human, open-label, Phase 1/2 dose escalation and multiple expansion cohort study designed to evaluate the safety and efficacy of NUV-422. The study population is comprised of adults with recurrent or refractory high-grade gliomas (HGGs), metastatic breast cancer (mBC), with and without brain metastases, and recurrent or refractory metastatic castration-resistant prostate cancer (mCRPC). All patients will self-administer NUV-422 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.

  • Conditions: breast cancer, breast carcinoma, breast tumor, cancer of breast, cancer of prostate, cancer of the breast, cancer of the prostate, glial cell tumors, glioma, glioma malignant, glioma mixed, malignant tumor of breast, prostate cancer, prostate neoplasm, prostatic cancer
  • Phase: I/II
  • Trial ID: NCT04541225
  • Protocol ID: 20-517

Enrolling

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Trial Description: This research study is studying a novel drug called ALRN-6924 as a possible treatment for resistant (refractory) solid tumor, brain tumor, lymphoma or leukemia. The drugs involved in this study are: - ALRN-6924 - Cytarabine (for patients with leukemia only)

  • Conditions: brain tumor, leukemia, lymphoma, solid tumor
  • Phase: I
  • Trial ID: NCT03654716
  • Protocol ID: 18-284

Not Enrolling

A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon having a tumor type, including but not limited to, non small cell lung cancer and head and neck cancer positive for specific activating MET, NTRK2, NTRK3, or DDR2 mutations, MET or KIT/PDGFRA/KDR gene amplification, selected gene rearrangements involving the MET, RET, AXL, NTRK1, or NTRK3 gene loci, or having loss of function mutations in the CBL gene. In addition patients with clear cell renal cell carcinoma refractory to angiogenesis inhibitors or metastatic prostate cancer with bone metastasis will be enrolled.

  • Conditions: advanced cancer
  • Phase: I
  • Trial ID: NCT02219711
  • Protocol ID: 14-308

Enrolling

Phase 1 Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer

Trial Description: This research study is studying an investigational drug called BMS-986158 as a possible treatment for pediatric solid tumors, lymphoma, or brain tumors.

  • Conditions: brain tumor pediatric, lymphoma, solid tumor childhood
  • Phase: I
  • Trial ID: NCT03936465
  • Protocol ID: 19-040

Enrolling

Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-MET EXON 14 Skip Mutations and c-MET Dysregulation Advanced Solid Tumors

Trial Description: The primary Phase 1 purpose of this study was to assess overall safety, tolerability and recommended Phase 2 dose (RP2D) of APL-101. The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations; individuals with cancers associated with c-Met amplifications; individuals with cancers associated with c-Met fusion

  • Conditions: advanced cancer, brain tumor, gastric cancer, gastroesophageal junction adenocarcinoma, glioblastoma multiforme, lung cancer, nsclc, renal cancer, solid tumor
  • Phase: I/II
  • Trial ID: NCT03175224
  • Protocol ID: 20-084

Enrolling

Phase I trial of ASTX727 in recurrent/progressive non-enhancing IDH mutant gliomas

Trial Description: this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients

  • Conditions: neurological cancer
  • Phase: I
  • Trial ID: NCT03922555
  • Protocol ID: 18-631

Enrolling

RELAY: Repeated Magnetic Resonance Imaging Examinations to Analyze and Assess Your Cancer: A Prospective Study on the Use of Serial Magnetic Resonance Imaging in the Assessment of Changes during Treatment with Radiation Therapy

Trial Description: This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (standard of care cancer treatment) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma. The research study procedures include three MRI scans (one pre treatment, during and post standard care cancer radiation therapy) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma. The research study procedures include: - Screening for eligibility - Three MRI scans

  • Conditions: esophageal cancer, glioblastoma, magnetic resonance imaging, mri, pediatric glioblastoma multiforme, prostate cancer, radiotherapy, vulvar cancer
  • Phase: I
  • Trial ID: NCT04188535
  • Protocol ID: 19-573

Enrolling

A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Trial Description: This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor

  • Conditions: infantile fibrosarcoma, infantile myofibromatosis, medullary thyroid cancer, papillary thyroid cancer, soft tissue sarcoma
  • Phase: I/II
  • Trial ID: NCT03899792
  • Protocol ID: 19-026

Enrolling

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Trial Description: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion

  • Conditions: adult solid tumor, breast cancer, cholangiocarcinoma, colorectal cancer, head and neck neoplasms, lymphoma large-cell anaplastic, melanoma, neuroendocrine tumors, non-small cell lung cancer, ovarian cancer, pancreatic cancer, papillary thyroid cancer, primary brain tumors, renal cell carcinoma, salivary gland cancers, sarcomas
  • Phase: II
  • Trial ID: NCT02568267
  • Protocol ID: 15-435

Not Enrolling

PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS

Trial Description: This is an open-label, nonrandomized, Phase 1 dose-escalation, dose-expansion, and Phase 2 study targeting tumors with FGF/FGFR aberrations. The purpose of the study is to evaluate the safety, tolerability, PK, pharmacodynamic, and anti-tumor activity of TAS-120 in patients with advanced solid tumors with and without FGF/FGFR-related abnormalities. The study will be conducted in 3 parts, (1) Dose escalation to determine the MTD and/ or RP2D of TAS-120 in which this part of the study has been completed; (2) Phase 1 expansion to further evaluate the safety and efficacy of RP2D

  • Conditions: activating mutations, brain tumor, cholangiocarcinoma, fgfr2 amplification, other tumor types with fgfr2 gene fusions, urothelial cancer
  • Phase: I
  • Trial ID: NCT02052778
  • Protocol ID: 14-135

Enrolling

Phase I Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

Trial Description: This research study seeks to gain new knowledge about the addition of a carefully targeted "boost" dose of radiation as a possible treatment for recurrent or metastatic head or neck cancer. The name of the study intervention involved in this study is stereotactic body radiotherapy, which is a way of delivering radiation in a more precisely targeted way and with a higher dose than conventional radiotherapy.

  • Conditions: head and neck cancer metastatic, head or neck cancer, recurrent head and neck carcinoma
  • Phase: I
  • Trial ID: NCT02474368
  • Protocol ID: 15-183

Not Enrolling

An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with REGN2810 in Subjects with Newly-Diagnosed Glioblastoma (GBM)

Trial Description: Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM

  • Conditions: glioblastoma
  • Phase: I/II
  • Trial ID: NCT03491683
  • Protocol ID: 18-377

Enrolling

A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First- Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)

Trial Description: A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  • Conditions: gastric adenocarcinoma, gastric cancer, gastroesophageal cancer
  • Phase: II
  • Trial ID: NCT04363801
  • Protocol ID: 20-433

Enrolling

OPTimizing Treatment Focused Genetic Testing IN Advanced Cancer- OPT-IN

Trial Description: This two-part randomized controlled trial aims to evaluate the impact of pre-test video education as compared to pre-test Chatbot education

  • Conditions: breast cancer, ovarian cancer, pancreatic cancer, prostate cancer
  • Phase: Not Applicable
  • Trial ID: NCT04066361
  • Protocol ID: 19-068

Enrolling

SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice

Trial Description: Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed opportunities to optimize symptom control. Growth in Internet access and proliferation of smartphones has created an opportunity to re-engineer cancer care delivery. Electronic symptom tracking and feedback is a promising strategy to improve symptom control. Electronic patient reported outcome (ePRO) monitoring of cancer symptoms has been shown to decrease symptom burden, improve quality of life, reduce acute care and even extend survival. SIMPRO will use functioning ePRO prototypes to create and refine the electronic symptom management system eSyM

  • Conditions: gastrointestinal cancer, gynecologic cancer, other cancer, thoracic cancer
  • Phase: Not Applicable
  • Trial ID: NCT03850912
  • Protocol ID: 18-734

Enrolling

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-Expressing Tumors (DESTINY-PanTumor02)

Trial Description: This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will enroll 7 tumor-specific cohorts: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumors. Study hypothesis: Trastuzumab deruxtecan will show meaningful clinical activity and a favorable risk benefit profile in selected HER2-expressing solid tumors.

  • Conditions: bladder cancer biliary tract cancer cervical cancer endometrial cancer ovarian cancer pancreatic cancer rare tumors
  • Phase: II
  • Trial ID: NCT04482309
  • Protocol ID: 21-051

Not Enrolling

A Phase II study of Lorlatinib (PF-06463922) in advanced ALK and ROS1 rearranged NSCLC with CNS metastasis in the absence of measurable extracranial lesions

Trial Description: This research study is studying a drug as a possible treatment for ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC). The following drug will be involved in this study : - Lorlatinib

  • Conditions: non-small cell lung cancer (nsclc)
  • Phase: II
  • Trial ID: NCT02927340
  • Protocol ID: 16-248

Enrolling

Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement (RESOURCE)

Trial Description: The purpose of this research is to understand how screening for patient resource needs followed by customized resource matching can improve outcomes for adults with breast, lung or gastrointestinal cancer.

  • Conditions: breast cancer, gastrointestinal cancer, lung cancer
  • Phase: Feasibility / Pilot
  • Trial ID: NCT04879927
  • Protocol ID: 20-437

Enrolling

Phase II Trial of Pembrolizumab in Central Nervous System Metastases from Multiple Histologies

Trial Description: This research study is studying Pembrolizumab as a possible treatment for this diagnosis for metastases in the central nervous system (brain and spinal cord).

  • Conditions: brain metastases
  • Phase: II
  • Trial ID: NCT02886585
  • Protocol ID: 16-153

Enrolling

Treatment response assessment maps (TRAMs) in the delineation of radiation necrosis from tumor progression after stereotactic radiation in patients with brain metastases: A prospective study

Trial Description: This research study is investigating the value of an imaging study of the brain called an MRI (which stands for magnetic resonance imaging), utilized in unique way, to delineate whether the tumor has recurred or whether radiation changes have occurred after a brain metastasis treated with focused radiation has enlarged.

  • Conditions: brain tumor
  • Phase: II
  • Trial ID: NCT04033497
  • Protocol ID: 19-191

Enrolling

A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated with Cranial Radiation for Brain Tumors

Trial Description: Background: - More children with cancer are surviving into adulthood. Some side effects from treatment go away quickly. But some problems may not go away or may only show up months or years later. These problems are called late effects. Late effects can cause difficulties in cognitive functions, such as attention and memory. Physical activity has been found to improve the attention and memory skills of children with Attention Deficit Hyperactivity Disorder (ADHD). Researchers want to see if physical activity can help with these cognitive problems in children with brain

  • Conditions: brain tumor
  • Phase: Not Applicable
  • Trial ID: NCT02153957
  • Protocol ID: 18-585

Enrolling

Clinical Onboard Utilization of Image Guided Radiation Therapy with Magnetic Resonance (CONFIRM): A Master Protocol

Trial Description: This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.

  • Conditions: bladder cancer, gastric cancer, in situ breast cancer, invasive breast cancer, larynx cancer, mantle cell lymphoma
  • Phase: I/II
  • Trial ID: NCT04368702
  • Protocol ID: 19-665

Not Enrolling

A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT, IN COMBINATION WITH CPI-444, AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS

Trial Description: This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with pembrolizumab (an anti-PD1 antibody), and in combination with ciforadenant and pembrolizumab.

  • Conditions: bladder cancer, cervical cancer, colorectal cancer, endometrial cancer, metastatic castration resistant prostate cancer, non-hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, renal cell cancer, sarcoma, squamous cell carcinoma of the head and neck, triple negative breast cancer
  • Phase: I
  • Trial ID: NCT03454451
  • Protocol ID: 18-335

Not Enrolling

Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB- 1158) as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid Tumors

Trial Description: This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors

  • Conditions: bladder cancer, colorectal cancer (crc), gastric cancer, head and neck cancer, lung cancer, mesothelioma, metastatic cancer, renal cell carcinoma (rcc), solid tumors, uc (urothelial cancer)
  • Phase: I
  • Trial ID: NCT02903914
  • Protocol ID: 17-427

Enrolling

MTG201-MPM-001Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men with Cancer and Androgen Deficiency

Trial Description: This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with incurable cancer who report fatigue and have low testosterone levels.

  • Conditions: cancer, fatigue, hypogonadism male
  • Phase: II
  • Trial ID: NCT04301765
  • Protocol ID: 20-183

Not Enrolling

Phase 1 Trial of Marizomib Alone and in Combination with Panobinostat for Children with Diffuse Intrinsic Pontine Glioma

Trial Description: This research study is evaluating the safety, tolerability and preliminary efficacy of the drugs marizomib and panobinostat in pediatric patients with diffuse intrinsic pontine glioma (DIPG). The names of the study drugs involved in this study are: - Marizomib - Panobinostat

  • Conditions: diffuse glioma, diffuse intrinsic pontine glioma, pediatric brain tumor, pediatric brainstem glioma, pediatric brainstem gliosarcoma recurrent, pediatric cancer
  • Phase: I
  • Trial ID: NCT04341311
  • Protocol ID: 19-654

Not Enrolling

A Phase I-II, First-in-Human Study of A166 in Patients with Locally Advanced/Metastatic Solid Tumors which are Human Epidermal Growth Factor Receptor 2 (HER2)-Positive who did not Respond or Stopped Responding to Approved Therapies and Patients with HER2 Positive (by ISH or NGS) or Low Expressing (b

Trial Description: Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity

  • Conditions: bile duct cancer, bladder cancer, breast neoplasm malignant primary, cervical cancer, cholangiocarcinoma, colo-rectal cancer, head and neck cancer, head and neck carcinoma, her-2 gene amplification, her2 gene mutation, her2 positive gastric cancer, her2-positive breast cancer, larynx cancer, lip cancer stage i, liver cancer, lung cancer, mouth cancer, mucinous adenocarcinoma gastric, mucinous breast cancer recurrent, mucoepidermoid carcinoma, palate cancer, pancreatic cancer, primary peritoneal carcinoma, prostate cancer, rare diseases, rectal cancer, rectal cancer stage i, rectal cancer stage ii, rectal cancer stage iii, recurrent breast cancer, recurrent colon cancer, recurrent gastric cancer, recurrent ovarian carcinoma, recurrent prostate cancer, recurrent renal cell cancer, salivary gland cancer, salivary gland carcinoma, salivary gland neoplasms, salivary gland tumor, skin cancer, solid tumor, tongue cancer, tonsil cancer, urologic cancer
  • Phase: I/II
  • Trial ID: NCT03602079
  • Protocol ID: 18-421

Enrolling

A Phase Ib/II study of pembrolizumab, ibrutinib and rituximab in recurrent primary central nervous system lymphoma (PCNSL

Trial Description: This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: - Pembrolizumab (MK3475) - Ibrutinib - Rituximab

  • Conditions: primary central nervous system lymphoma, recurrent cancer
  • Phase: I/II
  • Trial ID: NCT04421560
  • Protocol ID: 20-144

Not Enrolling

A Phase 1, Open-Label, Dose-Finding Study of ASN007 in Patients with Advanced Solid Tumors

Trial Description: The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.

  • Conditions: cancer, colon cancer, colon cancer liver metastasis, colonic neoplasms, malignancy, metastatic cancer, metastatic colon cancer, metastatic lung cancer, metastatic melanoma, metastatic nonsmall cell lung cancer, metastatic pancreatic cancer, neoplasia, neoplasm, neoplasm metastasis, non small cell lung cancer metastatic, pancreas adenocarcinoma, pancreas cancer, pancreas neoplasm, pancreatic cancer
  • Phase: I
  • Trial ID: NCT03415126
  • Protocol ID: 18-228

Enrolling

A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS

Trial Description: This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody

  • Conditions: bladder cancer, colorectal cancer, head and neck cancer, melanoma, non-small cell lung cancer, other solid cancers, renal cancer, triple negative breast cancer
  • Phase: I
  • Trial ID: NCT03289962
  • Protocol ID: 18-051

Not Enrolling

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)

Trial Description: The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors. PROCLAIM: PRObody CLinical Assessment In Man CX-2009 clinical trial 001 PROBODY is a trademark of CytomX Therapeutics, Inc

  • Conditions: breast cancer, head and neck cancer, non small cell lung cancer, ovarian cancer, solid tumor adult
  • Phase: I/II
  • Trial ID: NCT03149549
  • Protocol ID: 17-368

Enrolling

Phase 2 study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) inhibitor, plus Carboplatin in patients with advanced, metastatic Salivary Gland Carcinoma

Trial Description: This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: - 9-ING-41 (a GSK-3β inhibitor) - Carboplatin chemotherapy

  • Conditions: adenoid cystic carcinoma, metastatic cancer, recurrent salivary gland cancer, salivary gland cancer
  • Phase: II
  • Trial ID: NCT05010629
  • Protocol ID: 21-384

Not Enrolling

A Phase I Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients with Advanced Cancers

Trial Description: This is an open-label, single arm, dose escalation study in patients with advanced cancers.

  • Conditions: cancer
  • Phase: I
  • Trial ID: NCT02552953
  • Protocol ID: 15-281

Not Enrolling

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination with AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors - OLAPCO (Olaparib Combinations)

Trial Description: The primary objective of this phase II trial is to determine tumor overall response rate (ORR) in molecularly selected patients with measurable disease as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST), before versus after 16 weeks of treatment across tumor types in each arm of the study

  • Conditions: cancer
  • Phase: II
  • Trial ID: NCT02576444
  • Protocol ID: 16-314

Enrolling

A phase II study of the CDK4/6 inhibitor abemaciclib in patients with solid tumors harboring genetic alterations in genes encoding D­type cyclins or amplification of CDK4 or CDK6

Trial Description: This research study is studying a targeted therapy as a possible treatment for cancer abnormality in one of the following genes: CCND1, CCND2, CCND3, CDK4, or CDK6. The drug involved in this study is: -Abemaciclib

  • Conditions: cancer
  • Phase: II
  • Trial ID: NCT03310879
  • Protocol ID: 17-343